Your session is about to expire
← Back to Search
Sodium Channel Blocker
Active drug for Mitral Regurgitation (REIN-MR Trial)
Phase 4
Waitlist Available
Led By Raj Baljepally, MD
Research Sponsored by University Cardiology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up t = 90 day
Awards & highlights
REIN-MR Trial Summary
The purpose of this study is to find out whether mitral regurgitation (or a leaky heart valve) caused by ischemic heart disease (decreased blood flow to heart muscle) will improve after administration of ranolazine.
Eligible Conditions
- Mitral Regurgitation
REIN-MR Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ t = 90 day
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~t = 90 day
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
effective regurgitant orifice by echocardiography
proximal isovelocity surface area by echocardiography
Secondary outcome measures
Rose Dyspnea Scale
Seattle Angina Questionnaire
Other outcome measures
Adverse Reactions
REIN-MR Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Active drugActive Control1 Intervention
Ranolazine therapy for three months
Group II: Sugar PillPlacebo Group1 Intervention
sugar pill therapy for three months
Find a Location
Who is running the clinical trial?
University CardiologyLead Sponsor
Raj Baljepally, MDPrincipal InvestigatorUniversity Cardiology
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger